NYSE · Healthcare
Elanco Animal Health Inc (ELAN)
As-reported financials and recent SEC filings for Elanco Animal Health Inc, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$4.71B
Net income
$-232.0M
Net margin
-4.9%
Diluted EPS
$-0.47
ROE
-3.5%
P/E (TTM)
—
Market cap
$12.27B
Debt / equity
0.6×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $4.71B | $4.44B | $4.42B | $4.41B | $4.76B |
| Gross profit | $2.59B | $2.44B | $2.49B | $2.50B | $2.63B |
| Operating income | — | — | — | — | — |
| Net income | $-232.0M | $338.0M | $-1.23B | $-78.0M | $-483.0M |
| Diluted EPS | $-0.47 | $0.68 | $-2.50 | $-0.16 | $-0.99 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-16
View on EDGAR →42026-06-16
View on EDGAR →42026-06-16
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →SD2026-05-27
View on EDGAR →8-K2026-05-27
View on EDGAR →Go deeper on ELAN
Search Elanco Animal Health Inc’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.